Nexalin Technology Supply Chain
Supply Chain of Nexalin Technology (NXL) as of Oct 17, 2026.
Get this data via API
Financial Data API
Supply Chain
-
Last updated:
Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Nexalin Technology Stock analysis
What does Nexalin Technology do? Nexalin Technology Inc, headquartered in Laguna Niguel, California, designs and develops neurostimulation products within the US health care sector. Listed on September 16, 2022, the company employs six full-time staff members. Its flagship device, Generation 1, utilizes bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The non-invasive system applies a high-frequency, charge-balanced electrical current waveform via head electrodes, offering relief without adverse side effects. Additionally, Nexalin is designing clinical trials for Generation 2, targeting substance use disorders, particularly opiate abuse, as well as chronic pain, Alzheimer’s disease, and dementia. These devices operate using varying voltages and frequencies to address mental health issues effectively. Nexalin Technology is one of the most popular companies on Eulerpool.
All Key Metrics — Nexalin Technology
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth